Oligodendroglioma staging: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
Michael Maddaleni (talk | contribs)
nocaptcha
16,504 edits
Created page with "{{CMG}} {{Oligodendroglioma}} ==Overview== ==Histopathological Grading== The histopathologic grading of oligodendrogliomas is controversial. Currently the most commonly use..."
 
 
(9 intermediate revisions by 5 users not shown)
Line 1: Line 1:
{{CMG}}
__NOTOC__
{{Oligodendroglioma}}
{{Oligodendroglioma}}
{{CMG}}{{AE}}{{S.M.}}{{SR}}


==Overview==
==Overview==
There is no established [[system]] for the [[Staging (pathology)|staging]] of [[oligodendroglioma]].


==Histopathological Grading==
==Staging==
The histopathologic grading of oligodendrogliomas is controversial.  Currently the most commonly used grading schema is based on year 2007 [[World Health Organization]] (WHO) guidelines.  Oligodendrogliomas are generally dichotomized into grade II (low grade) and grade III (high grade) tumors.  The designation of grade III oligodendroglioma (high grade) generally subsumes the previous diagnoses of anaplastic or malignant oligodendroglioma.
There is no established [[system]] for the [[Staging (pathology)|staging]] of [[oligodendroglioma]].


Unfortunately, the WHO guidelines include subjective criteria in differentiating grade II and grade III tumors including the appreciation of “significant” hypercellularity and pleomorphism in the higher grade lesion.  In addition, the presence of low mitotic activity, vascular proliferation and necrosis, including pseudopallisading necrosis are insufficient by themselves to elevate the grade of these tumors.  This leads to inevitable interobserver variability in diagnosis by pathologists.  The ultimate responsibility for making treatment decisions and interpretation of these diagnoses lies with the oncologist in consultation with the patient and their family.   
==References==
{{Reflist|2}}


It has been proposed that [[World Health Organization|WHO]] guidelines should contain a category for grade IV oligodendrogliomas which essentially appear to be glial neoplasms with overwhelming features of [[glioblastoma multiforme]] (GBM) arising from known lower grade oligodendrogliomas or GBM with a significant proportion of oligodendroglial differentiation.  The diagnostic ultility of this latter category is uncertain as these tumors may behave either like glioblastoma or grade III oligodendrogliomas.  As such, this is an exceptionally unusual diagnosis. 
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}


The updated WHO guidelines published in 2007 recommends classifying such tumors for the time being as ‘glioblastoma with oligodendroglioma component’. <ref>{{cite journal |author=Louis D, Ohgaki H, Wiestler O, 'et al'' |title=The 2007 WHO Classification of Tumours of the Central Nervous System |journal=Acta Neuropathologica |volume=114 |issue=2 |pages=97-109 |year=2007 |pmid=17618441 |doi=10.1007/s00401-007-0243-4}}</ref> It remains to be established whether or not these tumors carry a better prognosis than standard glioblastomas.
[[Category:Neurological disorders]]
 
[[Category:Types of cancer]]
==References==
[[Category:Neurosurgery]]
{{Reflist|2}}
[[Category:Disease]]
[[Category:Mature chapter]]
[[Category:Up-To-Date]]
[[Category:Oncology]]
[[Category:Medicine]]
[[Category:Neurology]]
[[Category:Neurosurgery]]

Latest revision as of 04:30, 17 May 2019

Oligodendroglioma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Oligodendroglioma from other Diseases

Epidemiology & Demographics

Risk Factors

Screening

Natural History, Complications, and Prognosis

Diagnosis

Staging

History & Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Oligodendroglioma staging On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Oligodendroglioma staging

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Oligodendroglioma staging

CDC on Oligodendroglioma staging

Oligodendroglioma staging in the news

Blogs on Oligodendroglioma staging

Directions to Hospitals Treating Oligodendroglioma

Risk calculators and risk factors for Oligodendroglioma staging

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sara Mohsin, M.D.[2]Sujit Routray, M.D. [3]

Overview

There is no established system for the staging of oligodendroglioma.

Staging

There is no established system for the staging of oligodendroglioma.

References


Template:WikiDoc Sources

Retrieved from "https://www.wikidoc.org/index.php?title=Oligodendroglioma_staging&oldid=1568690"